ERBB2 and breast carcinoma: Talazoparib, another potent PARP inhibitor, was approved based on a Phase I trial (NCT03499353), which reported a median overall survival (OS) of 24.3 months in HER2‐negative advanced breast cancer patients, significantly outperforming the 6.3 months observed in those receiving standard chemotherapy.